// App-Quantinova.ai

CT306 : Radiolabeled anti-PSMA antibody J591 immunotherapy is associated with favorable circulating tumor cell (CTC) count control in men with castration-resistant prostate cancer

Researchers

Presenter

  • Pravin Date

Principal Investigators

  • Beerinder S. Karir

  • Jaspreet S. Batra

  • Yuliya Jhanwar

  • Himisha Beltran

  • David M. Nanus

  • Neil H. Bander

  • Scott T. Tagawa

Medical Centers

  • Weill Cornell Medical College, New York, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Metastatic castration-resistant prostate cancer

  • Solid malignancies

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • MLN591RL

  • Docetaxel

  • J591

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved